Forward Looking Statements

This Investor Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to Interpace Diagnostics Group, Inc.'s (the “Company's”) future financial and operating performance, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's ability to adequately finance the business, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other Securities and Exchange Commission (“SEC”) filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this presentation and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Overview

Interpace provides complex molecular analysis for the early diagnosis of cancer and development of targeted cancer therapeutics

**Biopharma Services Business**
Supporting clinical trials by providing lab testing services to biopharmaceutical companies for drug development

**Clinical Diagnostics Business**
Providing evidence-based, clinically beneficial molecular diagnostic tests and pathology services
Geographic Footprint

- Corporate headquarters in Parsippany, NJ
- CLIA/CAP facilities in:
  - Rutherford, NJ
  - Raleigh, NC
  - Pittsburgh, PA
- Capacity for growth
- More than 175 employees*

<table>
<thead>
<tr>
<th>Lab Locations</th>
<th>Pittsburgh, PA</th>
<th>Raleigh, NC</th>
<th>Rutherford, NJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>20,000 sq ft</td>
<td>24,900 sq ft</td>
<td>17,900 sq ft</td>
<td></td>
</tr>
<tr>
<td>50 FTE</td>
<td>25 FTE</td>
<td>55 FTE</td>
<td></td>
</tr>
</tbody>
</table>

*Includes field commercial teams
Recent Accomplishments—Interpace

- Diagnostic business revenue growth at 30%+ CAGR from 2015 - 2018
- Acquired CGIX biopharma lab services business targeting 2020 annual revenue to approx. $50M
- Funded CGIX acquisition and future growth with two of the top PE firms in lab space: Ampersand and 1315 Capital Partners ($47 M)
- GeneCast Biotechnology partnership in China supporting International expansion
- Two new Medicare thyroid approval codes: price increases in Dx: ThyraMIR to $3,000 and ThyGeNEXT to $2900.
- Added: Ron Rocca CEO of Exagen to Board; Fred Knechtel of GeneWiz as CFO; and Jeff Saltzman of CareDx as VP of Managed Care
Molecular tests that leverage the latest technology platforms to deliver accurate results and better assess the risk of cancer progression
We develop and commercialize molecular diagnostic tests, leveraging the latest technologies to help personalize medicine for better disease diagnosis and management.

**We Resolve Diagnostic Uncertainty**

- **Diagnostic Biopsy** → **Indeterminate Results**
- **Interpace Molecular Diagnostic Products** → **Improved Outcomes** → **Appropriate Surgery** → **Early Treatment** → **Significant Cost Savings**
- **Traditional Diagnostic Regimen** → **Worse Outcomes** → **Unnecessary Surgeries** → **Delayed Treatment** → **Wasted Resources**

**Our Capabilities Include:**

- Early cancer detection and its aggressive potential
- Predicting long-term outcomes
- Assigning a risk of malignancy to biopsied samples
- Multiple platforms to detect and prognose cancers
- Multiple platforms to detect and prognose cancers
- Offer tests with high positive and negative predictive values

**Our Uniqueness:** “We reduce uncertainty with accurate diagnostic and prognostic testing”
## Diagnostics Product Portfolio

<table>
<thead>
<tr>
<th>Indication</th>
<th>Diagnostic Test</th>
<th>Total Market Opportunity</th>
<th>Diagnostic Report</th>
<th>Lives Covered</th>
<th>Patents or Proprietary Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid Cancer</td>
<td>NGS Panel for Thyroid Cancer</td>
<td>$350 mn</td>
<td>Rules In Thyroid Cancer</td>
<td>Over 275 mn</td>
<td>1 US Patents Pending</td>
</tr>
<tr>
<td>Thyroid Cancer</td>
<td>MicroRNA Risk Classifier for Thyroid Cancer</td>
<td>$350 mn</td>
<td>Rules Out Thyroid Cancer</td>
<td>Over 275 mn</td>
<td>Proprietary Algorithm 2 US Patents Pending 5 ex-US Patents Pending</td>
</tr>
<tr>
<td>Esophageal Cancer</td>
<td>Risk-Stratifies for Esophageal Cancer</td>
<td>$1bn - $1.5bn</td>
<td>Rules In Higher Risk of Progression to Esophageal Cancer</td>
<td>Soft Launch in 2018</td>
<td>1 Patent Allowed 2 Patents Pending</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>Risk of New Primary Cancer Formation vs. Metastases or Recurrence</td>
<td>Up to $90mn</td>
<td>Rules In and Rules Out New Primary Cancer Formation</td>
<td>Over 100 mn</td>
<td>Proprietary Algorithm</td>
</tr>
</tbody>
</table>

### Other Proprietary Assets:

- + Lab information management system extracts results from database and allows efficient integration of molecular & clinical results
- + Extraction and microdissection methodology from slides, buffer and FFPE samples
- + Extensive experience in managing extremely low quantity fixative treated clinical specimens
### Diagnostics Pricing, Reimbursement, and Adoption

<table>
<thead>
<tr>
<th></th>
<th>ThyGeNEXT</th>
<th>ThyraMIR</th>
<th>PancreaGen</th>
<th>RespriDx</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>List Price</strong></td>
<td>$1,675</td>
<td>$4,000</td>
<td>$4,000</td>
<td>$4,500</td>
</tr>
<tr>
<td><strong>Typical Net Realized Price</strong></td>
<td>$600</td>
<td>$2,000</td>
<td>$2,600</td>
<td>$2,600</td>
</tr>
<tr>
<td><strong>Molecular Billing Code</strong></td>
<td>81445</td>
<td>PLA 0018U</td>
<td>81479</td>
<td>81479</td>
</tr>
</tbody>
</table>

### Insurance Coverage

**LabCorp**
- Geisinger Caring
- UnitedHealthcare
- Kaiser Permanente
- Various affiliates of: Blue Cross Blue Shield
- CareFirst
- NOVITAS Solutions Medicare
- Emblem Health
- Cigna
- Oxford Health Plans

**LabCorp**
- Geisinger Caring
- UnitedHealthcare
- Kaiser Permanente
- Various affiliates of: Blue Cross Blue Shield
- CareFirst
- NOVITAS Solutions Medicare
- Emblem Health
- Cigna
- Oxford Health Plans

**Humana**
- Various affiliates of: Blue Cross Blue Shield
- Tricare
- Galaxy Health Network
- ChoiceCare
- MultiPlan

**UnitedHealthcare**
- Independence Blue Cross
- Saint Barnabas Medical Center
- Fallon Health
- RW Barnabas Health
- Highmark

**Cigna**
- Various affiliates of: Blue Cross Blue Shield
- Horizon Blue Cross Blue Shield of New Jersey
Diagnoses Growth Opportunity—Barrett’s Esophagus

BE is often diagnosed in people who have long-term gastroesophageal reflux disease (GERD).

GERD occurs when stomach acid flows into the esophagus causing irritation.

BE is associated with an increased risk of developing esophageal cancer.

BarreGEN® is a cancer risk classifier for Barrett’s Esophagus

› Can help differentiate disease stages for better treatment regimen
› Currently assessing utility of BarreGEN in predicting recurrence of BE post treatment
› Cost effective solution and beneficial to patients
Diagnostics – Barrett’s Esophagus (BE)

A risk factor for esophageal cancer

15-30% Of adults in the US have gastroesophageal reflux disease (GERD)

10-15% Of adults with GERD can progress to BE

~3.3mn Adults in the US will be diagnosed with BE

~30x Increased risk of developing esophageal cancer if diagnosed with BE

1 in 5 Individuals with esophageal cancer will survive beyond 5 years

$1 - $1.5bn Market potential in the US

Percent Surviving 5 years after Diagnosed with Esophageal Cancer

19.9%
Barrett’s Studies Update

Ablation Study, UNC
→ Single site, pilot study aimed at determining association between ML and resistance/recurrence after ablation, pilot study
→ Underwent UNC scientific review
→ IRB submission, approval expected Jan 2020
→ Press release to announce 1/7/2020
→ Sample accrual to begin Q1 2020
→ Final samples expected second half 2020

Dallas Study
→ Finalized DALLAS Study protocol with KOL input (Q4 2019)
→ Sites: UNC, Cornell, UPenn, UCLA, Cleveland Clinic, U of Kansas, Columbia
→ Finalize budget based on site participants – in process
→ Execute clinical research contracts with institutions – in process
→ Begin specimen accrual Q1 2020
→ Phase 1 completion Q3 2020, Phase 2 completion Q1 2021
Pharma Solutions Business

Provide laboratory testing services to biopharma companies engaged in oncology and immuno-oncology clinical trials for therapeutic development
Pharma Solutions—Business Unit Overview

Morphology & Analytical Platforms
- Anatomic Pathology
- Cytogenetics
- FISH
- Flow Cytometry

CAP-Accredited Biorepository

Dedicated Informatics Experienced in Data Integration

Molecular Platforms
- Sequencing
- NanoString
- Microarray
- Real-time PCR
- RNA-seq

Medical & Scientific Expertise
- 16 MDs
- 19 PhDs

Actionable Data

Supporting approximately 225 clinical trials and studies focused on solid tumor and blood cancers, including 53 for immuno-oncology indications
Growing and Robust Customer Base

CONTRACTS WITH
9 OF 10
TOP BIOPHARMA COMPANIES

Approx. 225
CLINICAL TRIALS SUPPORTED WITH TESTING, GENOMIC SERVICES AND BIOMARKER CAPABILITIES

Select Customers
### Positioned to Benefit from Expanding Immuno-oncology Landscape

<table>
<thead>
<tr>
<th>Immuno-oncology drugs have the potential to impact up to</th>
<th>Immuno-oncology drug sales expected to reach</th>
</tr>
</thead>
<tbody>
<tr>
<td>60% of all cancer patients</td>
<td>$50BN by 2025</td>
</tr>
</tbody>
</table>

#### IDXG’s Pharma Solutions’ Extensive Approach for I-O:

<table>
<thead>
<tr>
<th>Technique</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunohistochemistry (“IHC”)</td>
<td>to detect critical biomarkers such as PD-L1 [FDA approved]</td>
</tr>
<tr>
<td>Immunophenotyping &amp; Flow Cytometry</td>
<td>to assess immune response against cancers</td>
</tr>
<tr>
<td>Transcriptome Profiling &amp; Sequencing via NGS</td>
<td>to measure expression levels of drug targets</td>
</tr>
<tr>
<td>Antigen &amp; Neoepitope Selection -AntigenID</td>
<td>to gauge the effectiveness of I-O therapies &amp; patient response</td>
</tr>
</tbody>
</table>

IDXG BioPharma offers **all PD-L1 companion diagnostic tests** available on the market for immuno-oncology.

IDXG BioPharma listed by Merck as a national reference lab for **KEYTRUDA** (expected sales of $5.8BN by 2025).
2020 Pharma Solutions & Diagnostics Commercial Integration

Pancreaticobiliary Cancers Program

1.) Program Goal: Provide the market with a solution that leverages both the Pharma Solutions development expertise and access to a Diagnostics solution and identified patients

2.) Target Market: Pharma/Biotech companies developing bile duct, pancreatic & hepatobiliary cancer therapies

3.) Market Opportunity: There are currently 310 bile duct, pancreatic or hepatobiliary cancer clinical studies being conducted by 200+ sponsors

Customer Value Proposition:

**ACCESS.** Customer is provided with access to 400 active PancraGEN customers and their patients

**SPEED.** This access will allow the customer to increase the speed at which it enrolls patients for its studies

**EFFICIENCY.** The “one stop shop” approach for development & patient recruitment will allow the customer to increase the efficiency of their drug development process
Biopharma business acquired July 15, 2019
Annual Revenue and Growth

Note: 2019E Revenue includes increase due to acquisition of BioPharma business from Cancer Genetics on July 15, 2019; 2019E Annual Revenue and % Growth assume midpoint of 2019 guidance.
Financial Overview

Share Price Performance

Public Market Overview
($ in millions, except per share data)

<table>
<thead>
<tr>
<th>Share Price:</th>
<th>$8.23</th>
</tr>
</thead>
<tbody>
<tr>
<td>52 Week High:</td>
<td>$10.40</td>
</tr>
<tr>
<td>52 Week Low:</td>
<td>$3.81</td>
</tr>
<tr>
<td>Fully Diluted Shares:</td>
<td>14.3</td>
</tr>
<tr>
<td>Fully Diluted Market Cap:</td>
<td>$118.0</td>
</tr>
<tr>
<td>Long-Term Debt:</td>
<td>-</td>
</tr>
<tr>
<td>Cash Balance (as of 9/30/19)</td>
<td>$4.2</td>
</tr>
<tr>
<td>Short Interest Ratio</td>
<td>1.40</td>
</tr>
</tbody>
</table>

Balance Sheet
($ in millions)

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>1Q19</th>
<th>2Q19</th>
<th>3Q19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$6.1</td>
<td>$9.1</td>
<td>$4.2</td>
<td>$2.4</td>
</tr>
<tr>
<td>Total Current Assets</td>
<td>$17.7</td>
<td>$22.2</td>
<td>$19.2</td>
<td>$20.6</td>
</tr>
<tr>
<td>Total Current Liabilities</td>
<td>$8.5</td>
<td>$9.8</td>
<td>$11.0</td>
<td>$17.3</td>
</tr>
<tr>
<td>Stockholders’ Equity</td>
<td>$33.0</td>
<td>$35.8</td>
<td>$30.8</td>
<td>$36.8</td>
</tr>
</tbody>
</table>

Gross Profit
($ in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$2,522</td>
<td>$6,444</td>
<td>$8,539</td>
<td>$11,699</td>
</tr>
</tbody>
</table>

Note: As of 2/12/20; Source: Bloomberg, Company Filings
Why Invest in Interpace Today?

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platform for Future Growth</td>
<td>Acquired CGIX Biopharma, Rosetta Assets</td>
</tr>
<tr>
<td>Target of $50M in Revenues and EBITDA B/E 2H-2020 Target</td>
<td></td>
</tr>
<tr>
<td>Sufficient Cash on Hand and Unlimited Availability</td>
<td></td>
</tr>
<tr>
<td>Upside Valuation Potential (vs. industry comps); 2x 2020 Revenues</td>
<td></td>
</tr>
<tr>
<td>Partnering with Leading P/E Firm</td>
<td>Ampersand Capital &amp; 1315 Capital</td>
</tr>
<tr>
<td>Proven Management Team</td>
<td></td>
</tr>
<tr>
<td>True Personal, Precision Medicine</td>
<td>Immuno-oncology, Companion Dx</td>
</tr>
<tr>
<td>Large Potential Pipeline Product</td>
<td>BarreGEN</td>
</tr>
</tbody>
</table>
Comparable Diagnostic/Biopharma Companies and Sales Multiples

Note: Data as of market close Sept 5, 2019

<table>
<thead>
<tr>
<th>Company</th>
<th>EV/LTM Revenue</th>
<th>EV/NTM Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castle Biosciences</td>
<td>4.0x</td>
<td>3.0x</td>
</tr>
<tr>
<td>Fulgent Genetics</td>
<td>10.9x</td>
<td></td>
</tr>
<tr>
<td>Genomic Health</td>
<td>5.8x</td>
<td>5.3x</td>
</tr>
<tr>
<td>LabCorp</td>
<td>2.2x</td>
<td>2.1x</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>2.0x</td>
<td>2.1x</td>
</tr>
<tr>
<td>NeoGenomics</td>
<td>9.3x</td>
<td>7.9x</td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td>2.5x</td>
<td>2.5x</td>
</tr>
<tr>
<td>Veracyte</td>
<td>9.7x</td>
<td>8.8x</td>
</tr>
<tr>
<td>Interpace</td>
<td>2.1x</td>
<td>1.1x</td>
</tr>
</tbody>
</table>
Near Term Business Drivers Expected

- Top Line Revenue Growth (Building Investor Confidence)
- Driving Performance and Results to EBITDA and Cash Flow Break Even
- Study Results Published: BarreGEN, PancraGEN and Thyroid Expanding Opportunity
- Improving Insurance Coverage Especially for Dx
- Building Joint Value Proposition of Dx and Biopharma
Thank you